Literature DB >> 30814351

Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.

Kenichiro Sato1, Tatsuo Mano1, Ryoko Ihara2, Kazushi Suzuki2, Naoki Tomita3, Hiroyuki Arai3, Kenji Ishii4, Michio Senda5, Kengo Ito6, Takeshi Ikeuchi7, Ryozo Kuwano7, Hiroshi Matsuda8, Takeshi Iwatsubo2,9, Tatsushi Toda1, Atsushi Iwata1.   

Abstract

BACKGROUND: Effect of serum calcium level to the incidence of mild cognitive impairment (MCI) conversion to early Alzheimer's disease (AD) remains uncertain.
OBJECTIVE: To investigate association between baseline serum calcium and the MCI conversion in the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) study cohort.
METHODS: In this sub-analysis of J-ADNI study, we reviewed data from MCI participants at baseline regarding their conversion to early AD during the 3 years of observation period and assessed the associated factors including serum calcium level. In addition, we compared our results from the J-ADNI study with the corresponding results from the North American (NA)-ADNI.
RESULTS: Of 234 eligible MCI participants from the J-ADNI cohort, 121 (51.7%) converted to AD during the first 36 months of observation. Using univariate analysis, being female, having shorter years of education, and lower serum calcium level were correlated with increased risk of MCI-to-AD conversion exclusively in J-ADNI cohort. The lower corrected serum calcium level remained as one of conversion-associated factors in the J-ADNI cohort even after adjustment for multiple confounding variables, although this was not observed in the NA-ADNI cohort.
CONCLUSION: Our findings suggest that lower serum calcium may be associated with an increased risk of MCI conversion to AD in Japanese cohorts. The reason for this correlation remains unclear and further external validation using other Asian cohorts is needed. It would be interesting for future AD studies to obtain serum calcium levels and other related factors, such as vitamin D levels, culture-specific dietary or medication information.

Entities:  

Keywords:  Alzheimer’s disease; Japanese Alzheimer’s Disease zzm321990Neuroimaging Initiative; calcium; conversion; mild cognitive impairment

Year:  2019        PMID: 30814351     DOI: 10.3233/JAD-181115

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Preoperative serum calcium could be a prognostic factor for surgical treatment of recurrent patellar dislocation: a retrospective study.

Authors:  Yi Qiao; Zipeng Ye; Junjie Xu; Xiuyuan Zhang; Jiebo Chen; Caiqi Xu; Song Zhao; Jinzhong Zhao
Journal:  BMC Musculoskelet Disord       Date:  2022-06-15       Impact factor: 2.562

2.  Analysis of the Relationship among Cognitive Impairment, Nutritional Indexes and the Clinical Course among COVID-19 Patients Discharged from Hospital-Preliminary Report.

Authors:  Jakub Klimkiewicz; Daniel Pankowski; Kinga Wytrychiewicz-Pankowska; Anna Klimkiewicz; Paulina Siwik; Joanna Klimczuk; Arkadiusz Lubas
Journal:  Nutrients       Date:  2022-04-11       Impact factor: 6.706

3.  Serum Calcium Predicts Cognitive Decline and Clinical Progression of Alzheimer's Disease.

Authors:  Ling-Zhi Ma; Zi-Xuan Wang; Zuo-Teng Wang; Xiao-He Hou; Xue-Ning Shen; Ya-Nan Ou; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-11-20       Impact factor: 3.911

Review 4.  Calcium: More Than Bone? Implications for Clinical Practice and Theory.

Authors:  Jacob M Hands; Lawrence S Moy
Journal:  J Clin Med Res       Date:  2021-05-25

5.  Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.

Authors:  Xincui Fang; Jing Zhang; Jianping Zhao; Litao Wang
Journal:  J Healthc Eng       Date:  2022-03-25       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.